Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Derm CasesDermatology / Rheumatology

Derm Cases · Dermatology / Rheumatology

OSCE — photosensitive plaques and scarring alopecia: cutaneous lupus classification and first-line therapy

An 8-minute OSCE station on ACLE/SCLE/DLE spectrum, work-up for systemic lupus, photoprotection and hydroxychloroquine stewardship, drug-induced SCLE, and pregnancy anti-Ro counselling.

8 minosce1 min readVerification in progress

Target exams

NEET-PGINICETUSMLEPLABMRCP
On this page
Study tools

Target exams

NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on ACLE/SCLE/DLE spectrum, work-up for systemic lupus, photoprotection and hydroxychloroquine stewardship, drug-induced SCLE, and pregnancy anti-Ro counselling.

Brief (to candidate)

A 34-year-old woman has annular polycyclic scaly plaques on the upper back and arms after sun exposure, mild arthralgia, and positive anti-Ro/SSA. She is considering pregnancy. A separate patient photo shows scarring discoid plaques on the scalp. You have 8 minutes to classify CLE, investigate for SLE, and manage including pregnancy counselling.

Candidate instructions

  1. Classify ACLE vs SCLE vs DLE (CCLE).
  2. Plan labs for systemic involvement.
  3. State first-line photoprotection + antimalarial therapy and monitoring.
  4. Identify drug-induced SCLE culprits.
  5. Counsel anti-Ro pregnancy risk (neonatal lupus/CHB).
  6. Address scarring alopecia urgency in DLE.
[2]

Examiner checklist (mark each domain / 10)

DomainKey actions expected
ClassificationACLE (malar/acute), SCLE (annular/psoriasiform photosensitive, anti-Ro), DLE/CCLE (scarring, scalp/face); Düsseldorf framework for subtypes including tumidus, profundus, chilblain LE[1][2]
Systemic screenANA, ENA (Ro/La), dsDNA, C3/C4, FBC, creatinine, urinalysis; ACLE often tracks active SLE; SCLE may be skin-limited or SLE-associated[2][9]
Histology/DIFInterface dermatitis, dermal mucin; lupus band (granular IgG/C3 at BMZ) on DIF supports diagnosis when indicated[1]
First-line RxStrict SPF 50+ photoprotection; hydroxychloroquine ≤5 mg/kg/day first-line with annual retinal screening; escalate MTX/MMF/anifrolumab/belimumab for refractory SLE-linked disease; thalidomide specialist option for refractory DLE[1][4][9]
Drug-inducedSCLE triggers include terbinafine, thiazides, calcium-channel blockers, TNF inhibitors — stop culprit[7]
PregnancyAnti-Ro/SSA: small risk neonatal lupus / congenital heart block; continue HCQ when appropriate; obstetric/fetal medicine co-management and fetal heart surveillance pathways[1][10]
CommunicationDLE scarring alopecia is irreversible — treat early; smoking cessation (reduces antimalarial efficacy); clear follow-up

Model key actions

  • Diagnose SCLE phenotype with anti-Ro and screen for SLE organ involvement.[1][2]
  • Start photoprotection + hydroxychloroquine with retinal monitoring; stop drug triggers if present.[4][7]
  • Counsel pregnancy/anti-Ro risks and co-manage; treat DLE aggressively to limit scarring.[10]

Common errors

  • Using high-potency topical steroids alone long-term without antimalarials/photoprotection.
  • Missing urinalysis/systemic work-up.
  • No retinal screening plan on hydroxychloroquine.
  • Ignoring drug-induced SCLE.
  • Inadequate anti-Ro pregnancy counselling.
[1] [4] [7] [10]
References6ShowHide
  1. [1]Vale ECSD, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. Anais Brasileiros de Dermatologia, 2023.PMID 36868923
  2. [2]Stull C, Sprow G, Werth VP. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. The Journal of rheumatology, 2023.PMID 36109075
  3. [4]Niebel D, de Vos L, Fetter T, et al. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. American Journal of Clinical Dermatology, 2023.PMID 37140884
  4. [7]He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Current opinion in rheumatology, 2018.PMID 29870500
  5. [9]Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 2024.PMID 37827694
  6. [10]Wainwright B, Bhan R, Trad C, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Dis Primers, 2020.PMID 31685414
PreviousOSCE — heliotrope rash and proximal weakness: dermatomyositis work-up and red flagsDermatology / RheumatologyNextOSCE — honey-crusted facial lesions: impetigo recognition and treatmentDermatology / Infectious Diseases / Paediatrics